Want to see TBPH full AI Analyst Report?
TBPH Stock Chart & Stats
$17.03
$0.03(0.18%)
At close: 4:00 PM EDT
$17.03
$0.03(0.18%)
Day’s Range― - ―
52-Week Range$13.08 - $21.03
Previous CloseN/A
Volume46.73K
Average Volume (3M)525.61K
Market Cap
$886.77M
Enterprise Value$562.05
Total Cash (Recent Filing)$387.66M
Total Debt (Recent Filing)$38.57M
Price to Earnings (P/E)16.1
Beta0.99
Next Earnings
Nov 10, 2026EPS Estimate
0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.06
Shares Outstanding51,918,755
10 Day Avg. Volume459,774
30 Day Avg. Volume525,607
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)3.17
Price to Sales (P/S)8.76
P/FCF Ratio3.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.00Price Target Upside-0.18% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)2.61
Revenue Forecast (FY)$110.32M
Bulls Say, Bears Say
Bulls Say
Current Cash GenerationPositive operating and free cash flow provide internal funding capacity and reduce reliance on external financing. This supports ongoing development, restructuring and transaction obligations, although sustainability depends on restoring the company’s longer-term cash conversion.
Low Financial LeverageThe conservatively levered balance sheet gives Theravance financial flexibility during portfolio reshaping and potential transaction completion. Limited debt reduces interest and refinancing pressure, leaving more capacity to fund development or absorb operating volatility.
Acquisition De-RiskingThe agreed all-cash acquisition can provide a defined path to shareholder liquidity while retaining contingent participation in ampreloxetine value. Board approval and a strategic review also indicate a structured response to portfolio and capital-allocation challenges.
Bears Say
Weak Operating ProfitabilityThe combination of softer revenue and a small operating loss indicates that reported net income is not fully supported by core operations. Earnings may therefore remain dependent on non-operating items, making profitability less durable than the headline margin suggests.
Cash Flow VolatilityAlthough current cash flow is positive, the sharp year-over-year decline and prior years of cash burn show limited consistency in cash generation. This volatility can constrain development investment and increase dependence on asset monetizations or strategic transactions.
Ampreloxetine Regulatory RiskThe pivotal trial miss materially raises uncertainty around ampreloxetine’s regulatory and commercial contribution. A further pivotal trial may offer a pathway, but it would require additional time, capital and execution, while approval and market entry remain unproven.
Theravance Biopharma News
TBPH FAQ
What was Theravance Biopharma’s price range in the past 12 months?
Theravance Biopharma lowest stock price was $13.08 and its highest was $21.03 in the past 12 months.
What is Theravance Biopharma’s market cap?
Theravance Biopharma’s market cap is $886.77M.
When is Theravance Biopharma’s upcoming earnings report date?
Theravance Biopharma’s upcoming earnings report date is Nov 10, 2026 which is in 66 days.
How were Theravance Biopharma’s earnings last quarter?
Theravance Biopharma released its earnings results on Aug 10, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of $0.072 by -$0.182.
Is Theravance Biopharma overvalued?
According to Wall Street analysts Theravance Biopharma’s price is currently Overvalued.
Does Theravance Biopharma pay dividends?
Theravance Biopharma does not currently pay dividends.
What is Theravance Biopharma’s EPS estimate?
Theravance Biopharma’s EPS estimate is 0.28.
How many shares outstanding does Theravance Biopharma have?
Theravance Biopharma has 51,918,755 shares outstanding.
What happened to Theravance Biopharma’s price movement after its last earnings report?
Theravance Biopharma reported an EPS of -$0.11 in its last earnings report, missing expectations of $0.072. Following the earnings report the stock price went down -0.118%.
Which hedge fund is a major shareholder of Theravance Biopharma?
Currently, no hedge funds are holding shares in TBPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Theravance Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$17.00 (-0.18% Downside)
$17.00 (-0.18% Downside)
Blogger Sentiment
Bearish
TBPH Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 79.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Theravance Biopharma
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
TBPH Stock 12 Month Forecast
Average Price Target
$17.00
▼(-0.18% Downside)
Technical Analysis
Ownership Overview
23.92% Insiders
9.94% Mutual Funds
48.24% Other Institutional Investors
5.37% Public Companies and
Individual Investors